BioStem Technologies (BSEM) director discloses 7,671 RSUs vesting in 2026
Rhea-AI Filing Summary
BioStem Technologies director Mark A. Glickman reported his initial equity position as a company insider. He holds 7,671 Restricted Stock Units, each representing a contingent right to receive one share of BioStem’s common stock. These RSUs vest on August 27, 2026, and are held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Glickman Mark A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Restricted Stock Units F2, F1 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 7,671 shares (Direct)
Footnotes (2)
- F1. These restricted stock units vest on August 27, 2026.
- F2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
Key Figures
Restricted Stock Units held: 7,671 units
Underlying common shares: 7,671 shares
RSU vesting date: August 27, 2026
3 metrics
Restricted Stock Units held
7,671 units
RSUs held directly by director Mark A. Glickman as reported on Form 3
Underlying common shares
7,671 shares
Each RSU represents a contingent right to receive one share of common stock
RSU vesting date
August 27, 2026
Vesting date for the reported 7,671 Restricted Stock Units
Key Terms
Restricted Stock Units, contingent right, beneficial ownership
3 terms
Restricted Stock Units financial
"These restricted stock units vest on August 27, 2026."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
beneficial ownership financial
"reported his initial equity position as a company insider and beneficial owner"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What insider position did Mark A. Glickman report at BioStem Technologies (BSEM)?
Mark A. Glickman, a director of BioStem Technologies, reported beneficial ownership of 7,671 Restricted Stock Units. These RSUs are linked to the company’s common stock and are reported as directly held equity-based compensation.
How many Restricted Stock Units does the BSEM director hold according to the Form 3?
The director holds 7,671 Restricted Stock Units. Each unit corresponds to a contingent right to receive one share of BioStem Technologies’ common stock, providing potential future share ownership once vesting conditions are satisfied.
When do Mark A. Glickman’s BioStem Technologies (BSEM) RSUs vest?
The reported Restricted Stock Units vest on August 27, 2026. Vesting is the date when the director earns the right to receive the underlying BioStem common shares associated with these equity awards, subject to the plan’s terms.
What does each Restricted Stock Unit represent for BioStem Technologies (BSEM) director Glickman?
Each Restricted Stock Unit represents a contingent right to receive one share of BioStem Technologies’ common stock. Actual share delivery typically occurs after the vesting date and any additional conditions in the equity plan are met.
Is the BSEM director’s RSU ownership reported as direct or indirect?
The Form 3 reports the 7,671 Restricted Stock Units as held under direct ownership. This indicates the director himself is the beneficial owner of these RSUs, rather than holding them through an intermediary entity or trust.
AI-generated analysis. How Rhea-AI works. Not financial advice.